SCHEMBL7143564

SCHEMBL7143564

CCOC(=O)c1ccc(NC(=O)CNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
TSHR P16473 2/20 0.59
POLB P06746 3/20 0.59
ALDH1A1 P00352 2/20 0.59
HTT P42858 1/20 0.59
RAB9A P51151 5/20 0.58
GAA P10253 2/20 0.55
MAPT P10636 4/20 0.53
KDM4E B2RXH2 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MAPK1 P28482 1/20 0.53
PDK1 Q15118 1/20 0.53
PDK2 Q15119 1/20 0.53
PDK3 Q15120 1/20 0.53
PDK4 Q16654 1/20 0.53
NPC1 O15118 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
CASP3 P42574 1/20 0.51
TRPV1 Q8NER1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL661882 0.89 MEN1 (0.62) MEN1KMT2AALDH1A1RAB9AMAPT
SCHEMBL25733667 0.89 MEN1 (0.54) MEN1KMT2APOLBALDH1A1HTT
SCHEMBL273218 0.86 PDK1 (0.60) MEN1KMT2ATSHRPOLBALDH1A1
SCHEMBL8693590 0.86 CA1 (0.54) MEN1KMT2APOLBALDH1A1RAB9A
SCHEMBL669133 0.84 PTPN11 (0.49) MEN1KMT2APOLBALDH1A1RAB9A
SCHEMBL19331720 0.84 CA1 (0.49) MEN1KMT2ATSHRALDH1A1HTT
SCHEMBL14679376 0.84 POLB (0.54) MEN1KMT2APOLBALDH1A1HTT
SCHEMBL7955826 0.83 CA1 (0.50) MEN1KMT2APOLBALDH1A1RAB9A
SCHEMBL10845806 0.81 POLB (0.53) MEN1KMT2ATSHRPOLBALDH1A1
SCHEMBL10850707 0.81 CA1 (0.50) MEN1KMT2ATSHRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP MEN1 2985/4885KMT2A 1971/4885TSHR 2814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.